Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Johannes Czernin, M.D.
Johannes Czernin, M.D.

Specialty:

Nuclear Medicine

General Information:

Gender:
Male
Language(s):
English, German

Affiliation(s):

Professor and Vice Chair, Department of Molecular and Medical Pharmacology
Director, Department of Molecular and Medical Pharmacology, Nuclear Medicine Clinic, Positron Emission Tomography/Computed Tomography
Associate Director, JCCC Cancer Molecular Imaging Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Residency:
Medicine/Nuclear Medicine, UCLA School of Medicine, 1993 - 1995
Medicine/Cardiology, Klinischen Abteilung Arbeitsmedizin, 1983 - 1989
Medical Degree
M.D., Universitat Wien Medizinische Fakultat, 1983

Certification(s):

Medical Board Certification(s):
Nuclear Medicine, American Board of Nuclear Medicine, 1996

Contact Information:

Nuclear Medicine Clinic:
(310) 794-1005 Patient appointments - Westwood
(310) 825-2344 Physician consultations
(310) 319-2242 Patient appointments - Santa Monica
Positron Emission Tomography/Computed Tomography:
(310) 794-1005 Patient appointments
(310) 825-2344 Physician consultations
Phone:
(310) 206-3226
Email:

Scientific Interest(s):

Dr. Johannes Czernin and his colleagues are studying the metabolic phenotype of tumor tissue and its relationship to the genotype.

The focus of Czernin's research is to refine the clinical role of molecular PET imaging. He has adopted a translational research approach by which radioactive ligand uptake in cell cultures determines the use of specific molecular imaging probes in small animals and later on in humans.

Selected Cancer-Related Publications:

Halpern BS, Yeom K, Fueger BJ, Lufkin RB, Czernin J, Allen-Auerbach M. Evaluation of suspected local recurrence in head and neck cancer: a comparison between PET and PET/CT for biopsy proven lesions. Eur J Radiol. 2007; 62(2): 199-204.

Kim SK, Allen-Auerbach M, Goldin J, Fueger BJ, Dahlbom M, Brown M, Czernin J, Schiepers C. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med. 2007; 48(2): 214-20.

Weber WA, Czernin J, Phelps ME. Prognostic significance of fluorodeoxyglucose uptake in non-small cell lung cancer. A blurry picture? Clin Cancer Res. 2007; 13(11): 3105-6.

Kesner AL, Dahlbom M, Huang SC, Hsueh WA, S Pio B, Czernin J, Kreissl M, Wu HM, Silverman DH. Semiautomated analysis of small-animal PET data. J Nucl Med. 2006; 47(7): 1181-6.

Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, Czernin J, Weber W. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006; 12(19): 5659-67.